Effect of Buspirone on the Behavioral Regulation of Rats in Low versus High Anxiety Conditions

Abstract

Introduction:

Buspirone (CAS 33386-08-2) is reported to have anxiolytic effects in humans and is mostly described for mild anxiety. To further explore the effects of buspirone on different levels of anxiety, the effect of buspirone was evaluated in two different conditions of the open field which were distinguished as low and high anxiety (enclosed and exposed open field, respectively).

Materials and methods:

Twenty-eight albino Wistar rats (350–400 g) were tested in two different arena settings, an enclosed and an exposed open field. Fourteen animals were initially injected with 1 ml saline while the others (n = 14) received buspirone 3 mg/kg.

Results:

The data showed clear differences in the two open-field settings, suggesting a higher anxiety level in the exposed open field. In addition, correlation analysis showed that the two anxiety tests measure different aspects of anxiety. Buspirone treatment reduced the behavioral activity in both the enclosed and exposed open field, which is generally interpreted as an anxiogenic effect. However, buspirone increased the time in the center areas and decreased the frequencies in the outer regions. These behavioral changes are generally seen as an anxiolytic effect. Correlation analysis showed that buspirone treatment disrupted the relation between indices of anxiety.

Conclusion:

These results showed that in an open-field setting buspirone appears to have a dual effect. The reduced activity and increase in time spent in the center areas are indicative of both an anxiogenic and an anxiolytic effect, respectively. This was found in both open-field settings, suggesting that the effects of buspirone are independent of the anxiety level.

Key words

Anxiolytics - Buspirone, anxiety conditions, rat - CAS 33386-08-2

• References

• 1 Arakawa H. Changes in the pattern of exploratory behavior are associated with the emergence of social dominance relationships in male rats. Dev Psychobiol. 2006; 48: 39-47
• 2 Blanchard RJ, Yudko E, Dulloog L, Blanchard DC. Defense changes in stress nonresponsive subordinate males in a visible burrow system. Physiol Behav. 2001; 72: 635-642
• 3 Blokland A, Lieben C, Deutz NE. Anxiogenic and depressive-like effects, but no cognitive deficits, after repeated moderate tryptophan depletion in the rat. J Psychopharmacol. 2002; 16: 39-49
• 4 Cervo L, Munoz C, Bertaglia A, Samanin R. Alnespirone and buspirone have anxiolytic-like effects in a conflict procedure in rats by stimulating 5-HT(lA) receptors. Behav Pharmacol. 2000; 11: 153-160
• 5 Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev. 2006; 3 CD006115
• 6 Collinson N, Dawson GR. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(lA) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(lA) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635. Psychopharmacology (Berl). 1997; 132: 35-43
• 7 Crawley JN. Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev. 1985; 9: 37-44
• 8 Cruz AP, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav. 1994; 49: 171-176
• 9 Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology (Berl). 1995; 118: 316-323
• 10 De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR. 5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol. 2004; 14: 487-495
• 11 Dember WN. Response by the rat to environmental change. J Comp Physiol Psychol. 1956; 49: 93-95
• 12 Ennaceur A, Michalikova S, Chazot PL. Models of anxiety: responses of rats to novelty in an open space and an enclosed space. Behav Brain Res. 2006; 171: 26-49
• 13 Ettenberg A, Bernardi RE. Anxiolytic-like actions of buspirone in a runway model of intravenous cocaine self-administration. Pharmacol Biochem Behav. 2006; 85: 393-399
• 14 Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs. 1986; 32: 114-129
• 15 Goldberg HL, Finnerty R. Comparison of buspirone in two separate studies. J Clin Psychiatry. 1982; 43: 87-91
• 16 Graeff FG, Netto CF, Zangrossi H Jr. The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev. 1998; 23: 237-246
• 17 Grundmann O, Kelber O, Butterweck V. Effects of St. John’s wort extract and single constituents on stress-induced hyperthermia in mice. Planta Med. 2006; 72: 1366-1371
• 18 Grundmann O, Nakajima J, Seo S, Butterweck V. Anti-anxiety effects of Apocynum venetum L. in the elevated plus maze test. J Ethnopharmacol. 2007; 110: 406-411
• 19 Hall C. Emotional behavior in the rat. I. Defecation and urination as measures of individual differences in emotionality. J Comp Psychol. 1934; 18: 385-403
• 20 Hashimoto T, Hamada C, Wada T, Fukuda N. Comparative study on the behavioral and EEG changes induced by diazepam, buspirone and a novel anxioselective anxiolytic, DN-2327, in the cat. Neuropsychobiology. 1992; 26: 89-99
• 21 Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav. 1996; 54: 21-30
• 22 Hooks MS, Jones GH, Juncos JL, Neill DB, Justice JB. Individual differences in schedule-induced and conditioned behaviors. Behav Brain Res. 1994; 60: 199-209
• 23 Hranilovic D, Cicin-Sain L, Bordukalo-Niksic T, Jernej B. Rats with constitutionally upregulated/downregulated platelet 5HT transporter: differences in anxiety-related behavior. Behav Brain Res. 2005; 165: 271-277
• 24 Jacobson LH, Bettler B, Kaupmann K, Cryan JF. Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety. Psychopharmacol-ogy (Berl). 2007; 190: 541-553
• 25 Kalueff AV, Tuohimaa P. Experimental modeling of anxiety and depression. Acta Neurobiol Exp (Wars). 2004; 64: 439-448
• 26 Kessler RC, Stang PE, Wittchen HU, Ustun TB, Roy-Burne PP, Walters EE. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry. 1998; 55: 801-808
• 27 Klebaur JE, Bardo MT. The effects of anxiolytic drugs on novelty-induced place preference. Behav Brain Res. 1999; 101: 51-57
• 28 Koob AO, Cirillo J, Babbs CF. A novel open field activity detector to determine spatial and temporal movement of laboratory animals after injury and disease. J Neurosci Methods. 2006; 157: 330-336
• 29 Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998; 139: 402-6
• 30 Lerman JA, Kaitin KI, Dement WC, Peroutka SJ. The effects of buspirone on sleep in the rat. Neurosci Lett. 1986; 72: 64-8
• 31 Mallo T, Alttoa A, Koiv K, Tonissaar M, Eller M, Harro J. Rats with persistently low or high exploratory activity: behaviour in tests of anxiety and depression, and extracellular levels of dopamine. Behav Brain Res. 2007; 177: 269-81
• 32 Mattila MJ, Aranko K, Seppala T. Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry. 1982; 43: 56-61
• 33 Mendelson WB, Martin JV, Rapoport DM. Effects of buspirone on sleep and respiration. Am Rev Respir Dis. 1990; 141: 1527-30
• 34 Newton RE, Casten GP, Alms DR, Benes CO, Marunycz JD. The side effect profile of buspirone in comparison to active controls and placebo. J Clin Psychiatry. 1982; 43: 100-2
• 35 Ninan PM. S. Buspirone and gepirone. In Schatzberg AF, Nemeroff CB. editors Textbook of psychopharmcology. 3rd ed Washington, DC: American Psychiatric Publishing; 2004. p 391-404
• 36 Picazo O, Fernandez-Guasti A. Antianxiety effects of diazepam and buspirone in rats under different hormonal status. Proc West Pharmacol Soc. 1998; 41: 205-6
• 37 Prickaerts J, Raaijmakers W, Blokland A. Effects of myocardial infarction and Captopril therapy on anxiety-related behaviors in the rat. Physiol Behav. 1996; 60: 43-50
• 38 Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003; 463: 3-33
• 39 Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B et al. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology (Berl). 2006; 185: 218-25
• 40 Romeo RD, Mueller A, Sisti HM, Ogawa S, McEwen BS, Brake WG. Anxiety and fear behaviors in adult male and female C57BL/6 mice are modulated by maternal separation. Horm Behav. 2003; 43: 561-7
• 41 Schwarting RK, Goldenberg R, Steiner H, Fornaguera J, Huston JP. A video image analyzing system for open field behavior in the rat focusing on behavioral asymmetries. J Neurosci Methods. 1993; 49: 199-210
• 42 Song C, Li X, Leonard BE, Horrobin DF. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res. 2003; 44: 1984-91
• 43 Sramek JJ, Zarotsky V, Cutler NR. Generalised anxiety disorder: treatment options. Drugs. 2002; 62: 1635-48
• 44 Treit D, Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav. 1988; 31: 959-62
• 45 Vaidya AH, Rosenthal DI, Lang W, Crooke JJ, Benjamin D, Ilyin SE et al. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action. Methods Find Exp Clin Pharmacol. 2005; 27: 245-55
• 46 van FJder Staay, Blokland A. Behavioral differences between outbred Wistar, inbred Fischer 344, brown Norway, and hybrid Fischer 344 x brown Norway rats. Physiol Behav. 1996; 60: 97-109
• 47 van FJder Staay, Kerbusch S, Raaijmakers W. Genetic correlations in validating emotionality. Behav Genet. 1990; 20: 51-62
• 48 Wada T, Fukuda N. Pharmacologic profile of a new anxiolytic, DN-2327: effect of Rol5-1788 and interaction with diazepam in rodents. Psychopharmacology (Berl). 1991; 103: 314-22
• 49 Warnick JE, Wicks RT, Sufka KJ. Modeling anxiety-like states: pharmacological characterization of the chick separation stress paradigm. Behav Pharmacol. 2006; 17: 581-7